TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06516783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Body Blue GEN 1.0 device
Description: Full body blue irradiation in the treatment of inflammatory skin diseases and chronic pruritus
Study: NCT00587561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition Interaction Training
Description: manualized group therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WLC
Description: wait-list control for 6 months, followed by the experimental group therapy
Study: NCT00859352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: oral tablets during 14 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
Study: NCT00906776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain PLUS
Description: Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone
Description: Autogenous bone application during periodontal surgery
Study: NCT04888780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The web-based Watson's Human Care Theory oriented training
Description: Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
Study: NCT01754012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
Study: NCT00694330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-K562 Vaccination
Description: Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
Study: NCT01041313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: 7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: 7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
Study: NCT01366989

Intervention type: DEVICE
Intervention: Radiographic evaluation of previously implanted patients
Description: Radiographs of the ankle
Study: NCT04657874

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bromelains and Escin Oral Tablet
Description: Supportive care after oral surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet without the active principle
Study: NCT04260646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enuresis Alarm Rodger and Timer watch (Rodger)
Description: Nocturnal enuresis fluid sensitive alarm and Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Timer watch (Rodger)
Description: Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Timer watch (Rodger)
Description: Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
Study: NCT02952885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
Study: NCT03067246

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VBM Intubating Laryngeal Tube
Description: The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel
Description: The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
Study: NCT01307436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epaxal
Description: 0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epaxal
Description: 0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix 720
Description: 0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
Study: NCT00853866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reboxetine
Description: single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reboxetine
Description: single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: placebo, 80 min before assessment of Jebsen Taylor test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo, 80 min before assessment of Jebsen Taylor test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS verum
Description: 20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
Study: NCT03476954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Impedance (RI)
Description: A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
Study: NCT00278395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given orally
Study: NCT01731821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticojejunostomy
Description: Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy
Description: Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.
Study: NCT00853866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS verum
Description: 20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: 30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS sham
Description: 30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
Study: NCT04440826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Food Meal
Description: Whole foods meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed Food Meal
Description: Processed food meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free and lactose-free
Description: Gluten-free and lactose-free food meal
Study: NCT02472717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
Study: NCT02154152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoeopathic Medicine causticum 200c
Study: NCT04423289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Farmalarm
Description: Monitoring after COVID-19 discharge from hospital via Farmalarm app
Study: NCT02783196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
Study: NCT02075944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity aerobic exercise
Study: NCT03277261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.
Study: NCT00711243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
Study: NCT03522506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 intravenous infusion.
Study: NCT00711243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
Study: NCT03277261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Film-coated tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Administered orally.
Study: NCT03522506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching given as saline intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching given as saline intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching given as saline intravenous infusion.
Study: NCT01428596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVAX
Description: Vaccine 1.0 ml SQ lower dose (10\^8 TU) at weeks 0, 8 and 16.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Saline solution 1.0 ml SQ at weeks 0, 8 and 16.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVAX
Description: Vaccine 1.0 ml SQ higher dose (10\^9 TU) at weeks 0, 8 and 16.
Study: NCT01163838

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
Study: NCT01961934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Acetate C11 PET/CT Imaging
Study: NCT03522506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching given as saline intravenous infusion.
Study: NCT01148017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Study: NCT01163838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 mg/kg every 2 weeks
Description: Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 mg/kg every 4 weeks
Description: Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mg/kg every 4 weeks
Description: Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mg/kg every 8 weeks
Description: Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
Study: NCT03522506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Placebo
Description: Modafinil placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Placebo
Description: Modafinil placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Placebo
Description: Modafinil placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Placebo
Description: Modafinil placebo-matching tablet.
Study: NCT03508076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Capsule
Description: Patients in this group would be treated with Vibrating Capsule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Capsule
Description: Patients in this group would be treated with Vibrating Capsule

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Capsule
Description: Capsules can't vibrate but look the same as Vibrating Capsule
Study: NCT01163838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8 mg/kg every 8 weeks
Description: Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 12 mg/kg every 8 weeks
Description: Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
Study: NCT01291355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific maternal position during the labor
Description: women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts.
Study: NCT04104152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-11
Description: A 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-12
Description: A 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-13
Description: A 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-14
Description: A 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-21
Description: A 5.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-22
Description: A 5.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-23
Description: A 5.0% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1902-24
Description: A 5.0% nicotine ENDS product
Study: NCT03397030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise Program
Description: The intervention will include a combination of both aerobic and body-weight based exercises. The aerobic portion of the intervention will include 5 days of light to moderate intensity walking for 30 mins. Intensity will be set at 40-60% of the individual's heart rate reserve. The body-weight based exercises will be done 3 times a week and will consist of 3 sets of 15 reps of bodyweight squats, incline push-ups, and hip thrusts. If these exercises cannot be performed, lower intensity exercises such as sit-to-stand, wall push up and pelvic tilt can be replaced. Individuals in this group will be given a pocket guide with instructions on how to safely perform the exercises and document their completion.
Study: NCT01159405

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeled (99mTc) GP (Glycopeptide)
Description: one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg \& 20 mg of GP will be injected